Form D — Quince Therapeutics, Inc.
0001662774-25-000035 · filed Jul 1, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $21,896,618
- Reported amount sold
- $11,488,304
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Quince Therapeutics, Inc.
- CIK
- 1662774
- Entity
- Corporation
- Jurisdiction
- CALIFORNIA
- Year incorporated
- —
- Address
- 611 Gateway Blvd., Suite 273
South San Francisco, California 94080 - Phone
- 415-910-5717
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Dirk Thye · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
-
Charles Ryan · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
-
David Lamond · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Margi McLoughlin · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Christopher Senner · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Luca Benatti · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Rajiv Patni · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
June Bray · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Una Ryan · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Brendan Hannah · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗